Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWOE62)

Drug Name

U3-1565 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Proheparin-binding EGF-like growth factor (HBEGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KHK-2866	DMR7EF6	Ovarian cancer	2C73	Phase 1	[3]
ASP0598	DM9QUCH	Chronic tympanic membrane perforation	AB13	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proheparin-binding EGF-like growth factor (HBEGF)	TT15SL0	HBEGF_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01290471) Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors. U.S. National Institutes of Health.
2	J Clin Oncol 31, 2013 (suppl; abstr 2519).
3	ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT04305184) A Phase 1/2, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of ASP0598 Otic Solution Following Topical Application Into the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP). U.S.National Institutes of Health.